Register now for our upcoming webinar

ABSTRACT: The current COVID-19 pandemic underlines the need for the rapid development of diagnostics and vaccines. Up to now, SARS-CoV-2 provoked more than 130 million infections and more than 2.9 million deaths globally. Antibodies do not only play a critical role in combating infections, but often form the basis for serological diagnostics. Peptide microarrays are an ideal tool to screen large libraries of peptides against serum antibodies on the epitope level. With the goal to identify potential discriminating serological markers for different COVID-19 disease phases (acute and convalescent) and clinical outcomes (mild and severe), we analyzed the epitope-specific antibody responses across the entire proteome of SARS-CoV-2. In a collaboration with the Charité in Berlin, our study identified a NSP15-derived peptide as potential marker for early and/or late COVID-19 disease detection. Moreover, we discovered several epitopes, which were significantly associated with severe COVID-19 disease.


Topics covered in this webinar :

   • Discover a new approach to characterizing and profiling antibody responses against SARS-CoV-2.

   • Get to know the benefits of using peptide microarrays for high-throughput screening of serological samples against multiple antigens.

   • How peptide microarrays can be used as a rapid-response research tool for immunogenic epitope detection of any pathogen.

Dr. Kirsten Heiss

Dr. Kirsten Heiss received her PhD in infectious diseases from the Ruprecht-Karls-University Heidelberg in 2006 working on the malaria-causing agent Plasmodium. Further Postdoc studies at the Institute of Immunology at University Hospital Hamburg-Eppendorf enabled her to combine infections with immunology. Back in Heidelberg in 2009, working as scientist at the Center for Infectious Diseases at the University Hospital Heidelberg, her research interests focused on vaccine development and the identification of novel targets for intervention strategies against malaria. In 2018, she joined the R&D unit of PEPperPRINT GmbH and is responsible for the discovery of novel antibody-mediated biomarkers in the field of autoimmune und infectious diseases.

Analzye anti-ASFV antibody responses with the PEPperCHIP® African Swine Fever Virus Microarray. Download the datasheet here.
Visit our digital booths and meet us at online at PEGS Boston on May 11-13, and at the AAI Virtual Immunology Meeting on May 12 - 16.
Are you a proactive excellent communicator with a life science background? Then join our BD team! Read the full job description here.